行情

ATHX

ATHX

Athersys Inc
NASDAQ

实时行情|Nasdaq Last Sale

0.5828
+0.0295
+5.33%
盘前: 0.5828 0 0.00% 08:55 05/16 EDT
开盘
0.5400
昨收
0.5533
最高
0.6000
最低
0.5400
成交量
59
成交额
--
52周最高
1.810
52周最低
0.4610
市值
1.47亿
市盈率(TTM)
-1.6426
分时
5日
1月
3月
1年
5年
Athersys to Participate in the H.C. Wainwright Global Investment Conference
CLEVELAND, May 13, 2022--Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida. The Company’s ma...
Business Wire · 3天前
BRIEF-Athersys Files For Common Stock Offering Of Up To $100 Million - SEC Filing
reuters.com · 3天前
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
BRIEF-Athersys Reports First Quarter 2022 Results
reuters.com · 05/06 12:21
Athersys Q1 EPS $(0.09) Beats $(0.10) Estimate
Athersys (NASDAQ:ATHX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 30.77 percent increase over losses of $(0.13) per share from the same
Benzinga · 05/06 12:11
BRIEF-Athersys Files For Mixed Shelf Of Up To $250 Million
reuters.com · 05/05 21:45
Athersys Q1 2022 Earnings Preview
Athersys (NASDAQ:ATHX) is scheduled to announce Q1 earnings results on Friday, May 6th, before market open. The consensus EPS Estimate is -$0.09 (+30.8% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 05/05 16:14
Earnings Outlook For Athersys
Athersys (NASDAQ:ATHX) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Athersys will report an earnings per share (EPS) of $-0.10.
Benzinga · 05/05 16:04
更多
暂无数据
了解ATHX最新的财务预测,通过ATHX每股收益,每股净资产,每股现金流等数据分析Athersys Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
75.00%买入
25.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ATHX价格均价为4.250,最高价位7.00,最低价为1.000。
最高7.00
均价4.250
最低1.000
现价0.5828
EPS
实际EPS
预期EPS
-0.08-0.06-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 189
机构持股: 6,114.31万
持股比例: 24.27%
总股本: 2.52亿
类型机构数股数
增持
32
171.85万
建仓
20
607.06万
减持
40
277.39万
平仓
30
159.50万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+4.50%
制药与医学研究
+1.39%
高管信息
Non-Executive Chairman/Independent Director
Ismail Kola
President/Chief Operating Officer
William Lehmann
Chief Executive Officer/Director
Daniel Camardo
Chief Financial Officer
Ivor Macleod
Executive Vice President/Chief Scientific Officer/Director
John Harrington
Director
Hardy Kagimoto
Director
Kenneth Traub
Independent Director
Katherine Kalin
Independent Director
Lorin Randall
Independent Director
Baiju Shah
Independent Director
Jane Wasman
Independent Director
Jack Wyszomierski
暂无数据
暂无数据
ATHX 简况
Athersys Inc是一家主要专注于再生医学领域的生物技术公司。该公司的MultiStem (invimestrocel)细胞疗法是同种异体干细胞候选产品,也是是其主打平台产品。MultiStem细胞疗法可用于治疗危重病症、神经系统疾病、炎症和免疫疾病、肺部疾病、心血管疾病和其他疾病。MultiStem细胞疗法是一种生物产品,它是由从成人骨髓中提取的人类干细胞制成,这些细胞也可以从其他组织中提取。该公司正在进行MultiStem细胞疗法治疗缺血性中风的III期临床试验,被称为 MASTERS-2。该公司目前处于临床开发阶段的项目包括缺血性中风、急性呼吸窘迫综合征(ARDS)和外伤。

微牛提供Athersys Inc(NASDAQ-ATHX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATHX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATHX股票基本功能。